Mask Cytotoxicity Testing: In Vitro Biocompatibility Evaluation to ISO 10993-5

Mask cytotoxicity testing determines whether materials and extracts from face masks release substances harmful to living cells, using in vitro cell culture methods specified in ISO 10993-5 and ISO 10993-12. As a mandatory element of biological evaluation for medical face masks, this testing supports regulatory submissions under the EU MDR, the US FDA 510(k) process, and NMPA registration in China. This article explains the technical principles, sample requirements, test methods, acceptance criteria, and practical applications of cytotoxicity testing for masks.

Technical Overview

Cytotoxicity testing is the foundational step in the biological evaluation of face masks that are marketed as medical devices. Medical face masks, surgical masks, and medical protective respirators are classified as surface devices contacting intact skin, with a contact duration that is typically limited to less than 24 hours. Under ISO 10993-1, this device category requires evaluation of cytotoxicity, sensitization, and irritation, and the cytotoxicity test is almost always performed first because it is fast, sensitive, and highly predictive of biological risk.

The test is conducted in accordance with ISO 10993-5 (Tests for in vitro cytotoxicity) and ISO 10993-12 (Sample preparation and reference materials), or their Chinese equivalents GB/T 16886.5 and GB/T 16886.12. Related methods are also described in ASTM F813 for direct contact evaluation and ASTM F895 for agar diffusion. The core principle is to expose a standardized mammalian cell line, most commonly L929 mouse fibroblasts, to a mask extract or to the mask material itself, then measure cell morphology and viability. Substances that leach from nonwoven filter layers, dyes, adhesives, nose foams, or antibacterial treatments can inhibit cell growth or cause cell death, indicating a potential biological hazard to the end user.

Testing Samples

Finished Mask Assemblies

Testing should be performed on the finished product in its final manufactured state, including all sterilization and packaging steps, because processing residues and secondary components are frequent sources of cytotoxicity.

• Complete mask body representing all laminate layers (spunbond polypropylene outer layers, melt-blown filter media, and inner comfort layers)
• Ear loops or head straps and their ultrasonic welding points
• Nose clips, nose foam padding, and fixation adhesives
• Printed logos, colored layers, and any decorative or functional coatings
• Antimicrobial or antiviral treated mask materials, where claimed

Component and Material Samples

During product development, individual raw materials can be screened separately to identify a problematic layer before tooling and production commitments are made.

• Raw nonwoven fabrics and melt-blown filter media from candidate suppliers
• Hot-melt adhesives, inks, colorants, and finishing agents
• Elastic band and nose foam materials
• Primary packaging materials that contact the finished mask

Sample Quantity and Condition

Typical submissions require approximately 15 to 30 finished masks, or a comparable mass of material (usually at least 6 g per extraction vehicle), sufficient to prepare extract at the mandated surface-area or mass-to-volume ratios. Samples must be representative of routine production and submitted in their final packaging; sterile products should be submitted sterile.

Testing Items

The core deliverable is the in vitro cytotoxicity result, reported either as a qualitative reactivity grade or a quantitative cell viability percentage. Common test configurations include:

• In vitro cytotoxicity by the extract method (MEM elution), the standard approach for masks
• Direct contact cytotoxicity test, where the specimen is placed directly on the cell monolayer
• Agar diffusion (indirect contact) test, generally less suitable for highly absorbent nonwoven materials
• Quantitative viability assessment using the MTT colorimetric assay alongside microscopic morphological grading
• Supporting extractables characterization and review as part of the broader ISO 10993 biological evaluation when required

Testing Methods

Sample Preparation and Extraction

Samples are cut into pieces under aseptic conditions and extracted following ISO 10993-12. For thin sheet materials below 0.5 mm in thickness, a ratio of 6 cm²/mL is applied; thicker materials use 3 cm²/mL; and porous, absorbent nonwovens may be dosed on a mass basis at 0.2 g/mL. The primary extraction vehicle is culture medium (MEM supplemented with serum), with 0.9% sodium chloride solution as a common secondary polar vehicle. The default extraction condition is 37°C ± 1°C for 24 hours ± 2 hours, which best simulates clinical skin contact; accelerated alternatives such as 50°C for 72 hours or 70°C for 24 hours may be used with justification.

Extract Test Procedure

L929 mouse fibroblasts are seeded into culture plates and grown to a standardized monolayer. The culture medium is then replaced with 100% test extract, and the plates are incubated at 37°C in a humidified 5% carbon dioxide atmosphere for 24 to 48 hours. At the end of exposure, cells are evaluated in two complementary ways:

• Microscopic morphological grading on the ISO 10993-5 reactivity scale: Grade 0 (none), Grade 1 (slight), Grade 2 (mild), Grade 3 (moderate), and Grade 4 (severe)
• Quantitative viability measurement by MTT assay, comparing absorbance of extract-treated cells against the blank vehicle control

Direct Contact and Agar Diffusion Options

In the direct contact test per ASTM F813 and ISO 10993-5, a sterile specimen is placed directly onto the cell monolayer and the zone of cell alteration beneath and around the sample is graded after incubation. In the agar diffusion test, an agar overlay protects the cells while diffusable toxicants pass through; this method is of limited value for mask materials because absorbent nonwovens can deplete the vital dye and distort results. For masks, the extract method remains the recognized reference technique.

Controls and Acceptance Criteria

Each run includes a negative control (high-density polyethylene, an established inert material), a positive control such as zinc sulfate solution or natural rubber latex extract, and a blank extraction vehicle. The test is valid only when controls perform within expected limits. Acceptance criteria widely applied to masks are:

• Qualitative result: reactivity no greater than Grade 2 (with Grade 0 or 1 being the common target for submission)
• Quantitative result: cell viability of at least 70% of the blank control, the threshold defined in ISO 10993-5:2009
• Chinese medical mask standards such as YY 0469 and GB 19083 align with the requirement that cytotoxicity reactivity does not exceed Grade 2

Applications

Cytotoxicity testing is used at multiple points across the mask product lifecycle:

• Regulatory submission as part of the biological evaluation file for CE marking under the EU Medical Device Regulation (MDR) 2017/745
• Biocompatibility documentation for US FDA 510(k) premarket notification of surgical masks and respirators with medical claims
• NMPA device registration in China for surgical masks (YY 0469) and medical protective masks (GB 19083), aligned with the GB/T 16886 series
• Registration support in other national programs referencing EN ISO 10993 or JIS-based biological evaluation frameworks
• Research and development screening of new nonwoven materials, dyes, adhesives, and antimicrobial finishes
• Change control when suppliers, materials, printing processes, or sterilization methods are modified
• Investigation of adverse skin reaction complaints and post-market quality surveillance

FAQ

Why do face masks require cytotoxicity testing?

When a mask is placed on the market as a medical device, its materials contact the user's skin for extended periods. Regulatory frameworks require demonstration that leachable substances, such as residual monomers, plasticizers, colorants, or sterilant residues, do not harm living tissue. The in vitro cytotoxicity test is the most direct and sensitive first-line screen for this risk.

Which cell line is used, and why?

The L929 mouse fibroblast cell line is the preferred and most widely accepted cell type for ISO 10993-5 testing because it is well characterized, reproducible, and historically validated across the medical device industry. Other established lines such as BALB/c 3T3 may be used with scientific justification.

How many samples are needed and how long does testing take?

A typical submission comprises 15 to 30 finished masks, depending on mask size and the number of extraction vehicles. The standard extract test generally requires 10 to 15 working days from sample receipt, including cell culture, extraction, exposure, and reporting. Accredited third-party laboratories can provide study plans and timelines in advance.

Do non-medical masks and industrial respirators require this test?

Cytotoxicity testing is triggered by medical device classification. Masks and respirators sold purely as occupational or consumer protective equipment are governed by their respective performance standards rather than the ISO 10993 biological evaluation matrix, although many manufacturers voluntarily perform the test to substantiate skin safety claims.

What are common causes of failure and how can they be addressed?

Failures are most often traced to colorants and printing inks, hot-melt or spray adhesives, antimicrobial chemical treatments, or residues from ethylene oxide sterilization (the latter additionally governed by ISO 10993-7). Remediation typically involves replacing the offending material, adjusting finishing processes, or extending sterilization aeration, followed by retesting of the modified product.